# Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers

> **NCT06630494** · PHASE1 · COMPLETED · sponsor: **3SBIO AU PTY LTD** · enrollment: 22 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Recombinant human thrombopoietin for injection (rhTPO)

## Key facts

- **NCT ID:** NCT06630494
- **Lead sponsor:** 3SBIO AU PTY LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-03
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-12-17
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630494, "Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06630494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*